Technical Analysis for HTBX - Heat Biologics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Historical HTBX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.88% | |
| Wide Bands | Range Expansion | 0.88% | |
| Oversold Stochastic | Weakness | 0.88% | |
| Crossed Above 200 DMA | Bullish | -5.67% | |
| Stochastic Reached Oversold | Weakness | -5.67% | |
| Wide Bands | Range Expansion | -5.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 3% | 3 days ago | |
| Down 2 % | 3 days ago | |
| Down 1% | 3 days ago | |
| Fell Below Previous Day's Low | 3 days ago | |
| Up 2% | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 09/27/2019
Heat Biologics, Inc. Description
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Ovarian Cancer Non Small Cell Lung Cancer Vaccine Cancer Treatment Vaccination HIV Platform Technology Bladder Cancer Cancer Vaccine Treatment Of Non Small Cell Lung Cancer Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.1 |
| 52 Week Low | 3.045 |
| Average Volume | 3,048,606 |
| 200-Day Moving Average | 8.40 |
| 50-Day Moving Average | 7.35 |
| 20-Day Moving Average | 9.03 |
| 10-Day Moving Average | 9.29 |
| Average True Range | 1.07 |
| ADX | 32.27 |
| +DI | 33.52 |
| -DI | 27.88 |
| Chandelier Exit (Long, 3 ATRs ) | 13.79 |
| Chandelier Exit (Short, 3 ATRs ) | 9.78 |
| Upper Bollinger Band | 12.37 |
| Lower Bollinger Band | 5.68 |
| Percent B (%b) | 0.34 |
| BandWidth | 74.07 |
| MACD Line | 0.29 |
| MACD Signal Line | 0.63 |
| MACD Histogram | -0.3447 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.81 | ||||
| Resistance 3 (R3) | 8.76 | 8.43 | 8.67 | ||
| Resistance 2 (R2) | 8.43 | 8.22 | 8.46 | 8.62 | |
| Resistance 1 (R1) | 8.21 | 8.09 | 8.26 | 8.26 | 8.58 |
| Pivot Point | 7.88 | 7.88 | 7.91 | 7.91 | 7.88 |
| Support 1 (S1) | 7.66 | 7.67 | 7.71 | 7.71 | 7.38 |
| Support 2 (S2) | 7.33 | 7.54 | 7.36 | 7.34 | |
| Support 3 (S3) | 7.11 | 7.33 | 7.29 | ||
| Support 4 (S4) | 7.16 |
